Maternal serum pentraxin 3 level in early pregnancy for prediction of gestational diabetes mellitus

Abstract

Background: Our study aimed to reveal the relationship of maternal pentraxin 3 (PTX3)'s serum concentrations in early pregnancy with gestational diabetes mellitus (GDM) and to explore its potential in the prediction of GDM.Methods: Totally 824 pregnant women were enrolled and divided into a GDM group and a normal glucose tolerance (NGT) group, whose maternal fasting serum PTX3 levels, plasma glucose and insulin were collected. The beta cell function index and quantitative insulin sensitivity check index (QUICKI) was calculated and a homeostatic model assessment of insulin resistance (HOMA-IR) was used with SPSS 22 software used for statistical analysis.Results: Of all subjects, 13.59% developed GDM. Compared to the NGT group, the PTX3 level was increased in the GDM group (1.48 vs. 1.52 ng/mL, P<0.05), and independently associated with the prediction of GDM (4.209, 95% CI, 1.756-10.091) (P=0.001). The area under receiver operating characteristic curve (AUROC) of the combined screening of PTX3 for GDM was incremented to 0.657 by the addition of maternal characteristics, and it reached a maximum of 0.743 in further combination with biochemical markers.Conclusions: Serum PTX3 levels in early pregnancy may provide a useful approach for early prediction of GDM.

Putrescine as a Novel Biomarker of Maternal Serum in First Trimester for the Prediction of Gestational Diabetes Mellitus: A Nested Case-Control Study

“…Therefore, their clinical benefit when applied to the most recent GDM definition has not yet been well investigated. Recently, a number of new markers have been evaluated for use in predicting GDM with variable success, such as protein biomarkers (23), adiponectin (24) and leptin (25), pentraxin 3 (26), trace elements (27), RNA (28), singlenucleotide polymorphisms (29), and other combined metabolite models (30)(31)(32)(33). The AUC values of some of these models can reach above 0.8.…”